{"filing":{"accession_number":"0000920148-26-000205","cik":"0000920148","ticker":"LH","company_name":"LABCORP HOLDINGS INC.","form":"8-K","filing_date":"2026-09-22","report_date":"2026-09-22","primary_document":"lh-20260922.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/920148/000092014826000205/lh-20260922.htm"},"events":[{"id":34364,"run_id":31622,"accession_number":"0000920148-26-000205","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"LabCorp discloses CMS's release of preliminary Clinical Laboratory Fee Schedule payment rates for 2027–2029 under PAMA, which the Company characterizes as imposing \"steep annual payment cuts that threaten patient access to laboratory services.\" The Company reaffirms its long-term financial outlook (5–8% revenue growth, 75–150 bps margin expansion, 8.5–11.5% EPS growth through 2029), indicating it has already factored this regulatory pressure into guidance. This is a material regulatory/operational event affecting the Company's business environment and reimbursement landscape, but it does not fit the specific categories of debt covenant breach, going concern, material impairment, or other defined event types. The disclosure is primarily forward-looking guidance and regulatory commentary rather than a discrete operational action or restructuring.","company_name":"LABCORP HOLDINGS INC.","ticker":"LH","filing_date":"2026-09-22","form":"8-K","submitted_at":null,"items":[{"id":38066,"accession_number":"0000920148-26-000205","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"LabCorp discloses CMS's release of preliminary Clinical Laboratory Fee Schedule payment rates for 2027–2029 under PAMA, which the Company characterizes as imposing \"steep annual payment cuts that threaten patient access to laboratory services.\" The Company reaffirms its long-term financial outlook (5–8% revenue growth, 75–150 bps margin expansion, 8.5–11.5% EPS growth through 2029), indicating it has already factored this regulatory pressure into guidance. This is a material regulatory/operational event affecting the Company's business environment and reimbursement landscape, but it does not fit the specific categories of debt covenant breach, going concern, material impairment, or other defined event types. The disclosure is primarily forward-looking guidance and regulatory commentary rather than a discrete operational action or restructuring.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T20:44:41.787611+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38066,"accession_number":"0000920148-26-000205","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"LabCorp discloses CMS's release of preliminary Clinical Laboratory Fee Schedule payment rates for 2027–2029 under PAMA, which the Company characterizes as imposing \"steep annual payment cuts that threaten patient access to laboratory services.\" The Company reaffirms its long-term financial outlook (5–8% revenue growth, 75–150 bps margin expansion, 8.5–11.5% EPS growth through 2029), indicating it has already factored this regulatory pressure into guidance. This is a material regulatory/operational event affecting the Company's business environment and reimbursement landscape, but it does not fit the specific categories of debt covenant breach, going concern, material impairment, or other defined event types. The disclosure is primarily forward-looking guidance and regulatory commentary rather than a discrete operational action or restructuring.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T20:44:41.787611+00:00","company_name":"LABCORP HOLDINGS INC.","ticker":"LH","filing_date":"2026-09-22"}]}